Incyte (NASDAQ:INCY – Get Free Report) will be issuing its quarterly earnings data before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.88 per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Incyte (NASDAQ:INCY – Get Free Report) last issued its quarterly earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.09). Incyte had a net margin of 16.17% and a return on equity of 12.56%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company posted $0.44 EPS. The business’s revenue was up 9.3% compared to the same quarter last year. On average, analysts expect Incyte to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Incyte Trading Up 1.0 %
INCY opened at $51.68 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.55 and a quick ratio of 3.36. Incyte has a fifty-two week low of $50.27 and a fifty-two week high of $75.74. The firm has a market capitalization of $11.60 billion, a PE ratio of 19.50, a P/E/G ratio of 1.18 and a beta of 0.65. The company’s 50-day moving average is $56.78 and its 200 day moving average is $57.70.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on INCY
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Featured Articles
- Five stocks we like better than Incyte
- Financial Services Stocks Investing
- MarketBeat Week in Review – 4/22 – 4/26
- How to Invest in Blue Chip Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Fintech Stocks With Good 2021 Prospects
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.